Locke Details Exciting Results for CAR T Cell Therapy in NHL – Targeted Oncology
|
Locke Details Exciting Results for CAR T Cell Therapy in NHL
Targeted Oncology The chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (KTE-C19) has shown promising results in patients with diffuse large B-cell lymphoma (DLBCL), primary mediastinal lymphoma, and transformed follicular lymphoma, according to … |
